Centrose

Executive Summary

Centrose is a Madison, Wisconsin-based biotechnology company developing Extracellular Drug Conjugates (EDCs), a novel class of therapeutics that act entirely outside the cell by targeting the cell surfaceome. Founded in 2009, the company aims to create safer and more potent cancer treatments by avoiding internalization and drug release. Its precision medicine platform targets interacting proteins on the cell surface, offering potential advantages over traditional antibody-drug conjugates. Despite being private with limited public disclosure, Centrose's innovative approach addresses key limitations in cancer therapy. The company's progress is closely watched by investors interested in next-generation biologics.

Upcoming Catalysts (preview)

• Q4 2026Series B Financing Round60% success
• Q2 2026IND Submission for Lead EDC Candidate40% success
• TBDStrategic Partnership with Major Pharma30% success